FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Equine Vet J / Associations between feeding and glucagon-like peptide-2 in ...
Equine veterinary journal2023; doi: 10.1111/evj.14004

Associations between feeding and glucagon-like peptide-2 in healthy ponies.

Abstract: Gastrointestinal peptides, such as glucagon-like peptide-2 (GLP-2), could play a direct role in the development of equine hyperinsulinaemia. Objective: To describe the secretory pattern of endogenous GLP-2 over 24 h in healthy ponies and determine whether oral administration of a synthetic GLP-2 peptide increases blood glucose or insulin responses to feeding. Methods: A cohort study followed by a randomised, controlled, cross-over study. Methods: In the cohort study, blood samples were collected every 2 h for 24 h in seven healthy ponies and plasma [GLP-2] was measured. In the cross-over study, 75 μg/kg bodyweight of synthetic GLP-2, or carrier only, was orally administered to 10 ponies twice daily for 10 days. The area under the curve (AUC ) of post-prandial blood glucose and insulin were determined before and after each treatment. Results: Endogenous [GLP-2] ranged from <0.55 to 1.95 ± 0.29 [CI 0.27] ng/mL with similar peak concentrations in response to meals containing 88-180 g of non-structural carbohydrate, that were ~4-fold higher (P < 0.001) than the overnight nadir. After GLP-2 treatment peak plasma [GLP-2] increased from 1.1 [0.63-1.37] ng/mL to 1.54 [1.1-2.31] ng/mL (28.6%; P = 0.002), and AUC was larger (P = 0.01) than before treatment. The peptide decreased (7%; P = 0.003) peak blood glucose responses to feeding from 5.33 ± 0.45 mmol/L to 5.0 ± 0.21 mmol/L, but not AUC (P = 0.07). There was no effect on insulin secretion. Conclusions: The study only included healthy ponies and administration of a single dose of GLP-2. Conclusions: The diurnal pattern of GLP-2 secretion in ponies was similar to other species with no apparent effect of daylight. Although GLP-2 treatment did not increase post-prandial glucose or insulin responses to eating, studies using alternative dosing strategies for GLP-2 are required.
© 2023 The Authors. Equine Veterinary Journal published by John Wiley & Sons Ltd on behalf of EVJ Ltd.
Get Full Text
Publication Date: 2023-09-13 PubMed ID: 37705248DOI: 10.1111/evj.14004Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research investigates the pattern of glucagon-like peptide-2 (GLP-2) secretion in healthy ponies over 24 hours and analyzes the effects of administering synthetic GLP-2 on blood glucose and insulin responses to feeding.

Research Design and Methods

  • The study involves a two-part process: a cohort study first, followed by a randomised, controlled, cross-over study.
  • The cohort study involves the collection of blood samples from seven healthy ponies every 2 hours over a span of 24 hours to determine the pattern of endogenous GLP-2 secretion.
  • The cross-over study focuses on the experimental administration of 75 μg/kg bodyweight of synthetic GLP-2 or a carrier, twice a day over 10 days, to a distinct group of 10 ponies.
  • For assessing the impact of feeding and GLP-2 treatment, the areas under the curve (AUC) of post-prandial (after-eating) blood glucose and insulin levels are determined before and after each treatment.

Key Findings

  • The study revealed that the secretion of endogenous GLP-2 in ponies ranged from <0.55 to 1.95 ± 0.29 ng/mL, with similar peak concentrations noted in response to meals containing 88-180 g of non-structural carbohydrate.
  • Upon administration of synthetic GLP-2, peak plasma concentration of GLP-2 increased by 28.6% (from 1.1 ng/mL to 1.54 ng/mL) and the AUC for GLP-2 was observed to be larger than prior treatment.
  • The administration of GLP-2 caused a 7% decrease in peak blood glucose responses to feeding (from 5.33 mmol/L to 5.0 mmol/L). However, there were no significant effects on the AUC of blood glucose or insulin secretion.

Conclusions

  • The secretory pattern of GLP-2 in ponies was observed to be consistent with other species and was not influenced by daylight.
  • Although the GLP-2 treatment did not markedly increase post-prandial glucose or insulin responses, further studies using different dosing strategies of GLP-2 are recommended.
  • Limitations of the study include its focus only on healthy ponies and the administration of a single dosage of synthetic GLP-2.

Cite This Article

APA
Sibthorpe PEM, Fitzgerald DM, Sillence MN, de Laat MA. (2023). Associations between feeding and glucagon-like peptide-2 in healthy ponies. Equine Vet J. https://doi.org/10.1111/evj.14004

Publication

Equine veterinary journal
ISSN: 2042-3306
NlmUniqueID: 0173320
Country: United States
Language: English

Researcher Affiliations

Sibthorpe, Poppy E M
  • School of Biology and Environmental Science, Queensland University of Technology, Brisbane, Queensland, Australia.
Fitzgerald, Danielle M
  • School of Biology and Environmental Science, Queensland University of Technology, Brisbane, Queensland, Australia.
Sillence, Martin N
  • School of Biology and Environmental Science, Queensland University of Technology, Brisbane, Queensland, Australia.
de Laat, Melody A
  • School of Biology and Environmental Science, Queensland University of Technology, Brisbane, Queensland, Australia.

Grant Funding

  • DP180102418 / Australian Research Council

References

This article includes 40 references
  1. Wallis N, Raffan E. The genetic basis of obesity and related metabolic diseases in humans and companion animals.. Genes 2020;11(11):1378.
  2. Renner S, Blutke A, Streckel E, Wanke R, Wolf E. Incretin actions and consequences of incretin-based therapies: lessons from complementary animal models.. J Pathol 2016;238(2):345-358.
  3. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance.. Physiol Rev 2018;98(4):2133-2223.
  4. Frank N, Tadros EM. Insulin dysregulation.. Equine Vet J 2014;46(1):103-112.
  5. McGowan CM. Endocrinopathic laminitis.. Vet Clin North Am Equine Pract 2010;26(2):233-237.
  6. de Laat MA, McGree JM, Sillence MN. Equine hyperinsulinemia: investigation of the enteroinsular axis during insulin dysregulation.. Am J Physiol Endocrinol Metab 2016;310(1):E61-E72.
  7. Chameroy KA, Frank N, Elliott SB, Boston RC. Comparison of plasma active glucagon-like peptide 1 concentrations in normal horses and those with equine metabolic syndrome and in horses placed on a high-grain diet.. J Equine Vet 2016;40:16-25.
  8. Bamford NJ, Baskerville CL, Harris PA, Bailey SR. Postprandial glucose, insulin, and glucagon-like peptide-1 responses of different equine breeds adapted to meals containing micronized maize.. J Anim Sci 2015;93(7):3377-3383.
  9. Fitzgerald DM, Pollitt CC, Walsh DM, Sillence MN, de Laat MA. The effect of different grazing conditions on the insulin and incretin response to the oral glucose test in ponies.. BMC Vet Res 2019;15(1):345.
  10. Brubaker PL, Crivici A, Izzo A, Ehrlich P, Tsai CH, Drucker DJ. Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2.. Endocrinology 1997;138(11):4837-4843.
  11. Tsai CH, Hill M, Asa SL, Brubaker PL, Drucker DJ. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice.. Am J Physiol 1997;273(1):E77-E84.
  12. Cheeseman CI. Upregulation of sglt-1 transport activity in rat jejunum induced by glp-2 infusion in vivo.. Am J Physiol Regul 1997;273(6):R1965-R1971.
  13. Ramsanahie A, Duxbury MS, Grikscheit TC, Perez A, Rhoads DB, Gardner-Thorpe J. Effect of glp-2 on mucosal morphology and sglt1 expression in tissue-engineered neointestine.. Am J Physiol Gastrointest 2003;285(6):G1345-G1352.
  14. de Laat MA, Fitzgerald DM, Sillence MN, Spence RJ. Glucagon-like peptide-2: a potential role in equine insulin dysregulation.. Equine Vet J 2018;50(6):842-847.
  15. Henneke DR, Potter GD, Kreider JL, Yeates BF. Relationship between condition score, physical measurements and body-fat percentage in mares.. Equine Vet J 1983;15(4):371-372.
  16. Carter RA, Geor RJ, Staniar WB, Cubitt TA, Harris PA. Apparent adiposity assessed by standardised scoring systems and morphometric measurements in horses and ponies.. Vet J 2009;179(2):204-210.
  17. National Research Council. Nutrient requirements of horses: 6th revised edition.. Washington, DC: The National Academic Press; 2007. p. 360.
  18. DaCambra MP, Yusta B, Sumner-Smith M, Crivici A, Drucker DJ, Brubaker PL. Structural determinants for activity of glucagon-like peptide-2.. Biochemistry 2000;39(30):8888-8894.
  19. Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase iv.. Nat Biotechnol 1997;15(7):673-677.
  20. Taylor-Edwards CC, Burrin DG, Holst JJ, McLeod KR, Harmon DL. Glucagon-like peptide-2 (glp-2) increases small intestinal blood flow and mucosal growth in ruminating calves.. J Dairy Sci 2011;94(2):888-898.
  21. Sigalet DL, Wallace L, De Heuval E, Sharkey KA. The effects of glucagon-like peptide 2 on enteric neurons in intestinal inflammation.. J Neurogastroenterol Motil 2010;22(12):1318.
  22. Warnken T, Huber K, Feige K. Comparison of three different methods for the quantification of equine insulin.. BMC Vet Res 2016;12(1):196.
  23. Xiao Q, Boushey RP, Drucker DJ, Brubaker PL. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans.. Gastroenterology 1999;117(1):99-105.
  24. Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2.. Annu Rev Physiol 2014;76:561-583.
  25. Hartmann B, Johnsen AH, Ørskov C, Adelhorst K, Thim L, Holst JJ. Structure, measurement, and secretion of human glucagon-like peptide-2.. Peptides 2000;21(1):73-80.
  26. Baldassano S, Amato A, Cappello F, Rappa F, Mule F. Glucagon-like peptide-2 and mouse intestinal adaptation to a high-fat diet.. J Endocrinol 2013;217(1):11-20.
  27. Sato S, Hokari R, Kurihara C, Sato H, Narimatsu K, Hozumi H. Dietary lipids and sweeteners regulate glucagon-like peptide-2 secretion.. Am J Physiol Gastrointest Liver Physiol 2013;304(8):G708-G714.
  28. Inabu Y, Murayama K, Inouchi K, Sugino T. The effect of tributyrin supplementation to milk replacer on plasma glucagon-like peptide 2 concentrations in pre-weaning calves.. Anim Sci J 2019;90:90-1192.
  29. Brubaker PL, Gil-Lozano M. Glucagon-like peptide-1: the missing link in the metabolic clock?. J Diabetes Investig 2016;7(1):70-75.
  30. Yoder SM, Yang Q, Kindel TL, Tso P. Differential responses of the incretin hormones gip and glp-1 to increasing doses of dietary carbohydrate but not dietary protein in lean rats.. Am J Physiol Gastrointest Liver Physiol 2010;299(2):G476-G485.
  31. Sibthorpe PEM. Studies on glucagon-like peptide-2 (GLP-2) and the equine gastrointestinal tract [cited 2023 Aug 14]. Available from: https://eprints.qut.edu.au/232700/. .
  32. Koopmann MC, Nelson DW, Murali SG, Liu X, Brownfield MS, Holst JJ. Exogenous glucagon-like peptide-2 (GLP-2) augments GLP-2 receptor mRNA and maintains proglucagon mrna levels in resected rats.. J Parenter Enteral Nutr 2008;32(3):254-265.
  33. Hu XF, Guo YM, Huang BY, Bun S, Zhang LB, Li JH. The effect of glucagon-like peptide 2 injection on performance, small intestinal morphology, and nutrient transporter expression of stressed broiler chickens.. Poultry Sci 2010;89(9):1967-1974.
  34. Drucker DJ, Boushey RP, Wang F, Hill ME, Brubaker PL, Yusta B. Biologic properties and therapeutic potential of glucagon-like peptide-2.. J Parenter Enteral Nutr 1999;23(5):S98-S100.
  35. Nguyen NQ, Debreceni TL, Bambrick JE, Chia B, Wishart J, Deane AM. Accelerated intestinal glucose absorption in morbidly obese humans: relationship to glucose transporters, incretin hormones, and glycemia.. J Clin Endocrinol Metab 2015;100(3):968-976.
  36. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2.. Proc Natl Acad Sci U S A 1996;93(15):7911-7916.
  37. Song Y, Day CM, Afinjuomo F, Tan JE, Page SW, Garg S. Advanced strategies of drug delivery via oral, topical, and parenteral administration routes: where do equine medications stand?. Pharmaceutics 2023;15(1):186.
  38. Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse.. Gut 2000;47(1):112-119.
  39. Hartmann B, Thulesen J, Kissow H, Thulesen S, Orskov C, Ropke C. Dipeptidyl peptidase iv inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice.. Endocrinology 2000;141(11):4013-4020.
  40. Bertin FR, de Laat MA. The diagnosis of equine insulin dysregulation.. Equine Vet J 2017;49(5):570-576.

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,001 horse owners like you who receive our email updates on horse health and nutrition.